The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Bakker, Marije F ^a   Verstappen, Suzanne M M ^a   Welsing, Paco M J ^a   Jacobs, Johannes W G ^a   Jahangier, Zalima N ^b   van der Veen, Maaike J ^c   Bijlsma, Johannes W J ^a   Lafeber, Floris P J G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TERGOOI HOSPITAL   (Netherlands)

^c ST JANSDAL HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; PROCOLLAGEN; PROTEOGLYCAN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SERUM; AGED; BLOOD; CARTILAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

EID: 79955497623     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3331     Document Type: Article

References (32)

1. Poole AR, Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994, 23:17-31. 10.1016/0049-0172(94)90081-7, 7939727.
2. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004, 294:145-153. 10.1016/j.jim.2004.09.005, 15637808.
3. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Van Wart H, Poole AR. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997, 99:1534-1545. 10.1172/JCI119316, 507973, 9119997.
4. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992, 90:2268-2277. 10.1172/JCI116113, 443378, 1281828.
5. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, Fraser GL, Brooks E, Tanzer M, Rosenberg LC, Dieppe P, Robin Poole A. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998, 102:2115-2125. 10.1172/JCI4853, 509166, 9854047.
6. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003, 48:3085-3095. 10.1002/art.11331, 14613270.
7. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2503-2511. 10.1002/1529-0131(200111)44:11<2503::AID-ART430>3.0.CO;2-P, 11710706.
8. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, Heinegard D, Saxne T. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995, 95:1071-1077. 10.1172/JCI117753, 441442, 7533784.
9. Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, Fearon U, Veale DJ. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007, 56:2919-2928. 10.1002/art.22843, 17763421.
10. Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S, Haavardsholm EA, Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009, 36:266-272. 10.3899/jrheum.080180, 19132792.
11. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006, 8:R31. 10.1186/ar1882, 1526568, 16507130.
12. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission: Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open label trial). Ann Rheum Dis 2007, 66:1443-1449. 10.1136/ard.2007.071092, 2111604, 17519278.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
14. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989, 1:1036-1038.
15. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
16. Bakker MF, Jacobs JWG, Bijlsma JWJ, Lafeber FPJG. Early good response to therapy in RA patients predicts a better long-term clinical course and less radiographic joint damage. Arthritis Rheum 2008, 58:S764-S765.
17. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006, 54:2496-2504. 10.1002/art.21977, 16868970.
18. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
19. Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, Reiner A, Tanzer M, Zukor D, Chen J, van Wart HE, Poole AR. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000, 43:673-682. 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8, 10728762.
20. van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010, 18:605-612. 10.1016/j.joca.2010.01.012, 20175979.
21. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol 2009, 19:273-282. 10.1007/s10165-009-0170-4, 19452245.
22. Landewe RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, Garnero P. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 2006, 65:40-44. 10.1136/ard.2004.035196, 1797999, 16126801.
23. Marotte H, Gineyts E, Miossec P, Delmas PD. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1197-1200. 10.1136/ard.2008.096057, 18713784.
24. Syversen SW, Haavardsholm EA, Boyesen P, Goll GL, Okkenhaug C, Gaarder PI, van der Heijde D, Kvien TK. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis 2010, 69:845-850. 10.1136/ard.2009.122325, 20233753.
25. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007, 56:3236-3247. 10.1002/art.22923, 17907159.
26. Visvanathan S, Marini JC, Smolen JS, St Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007, 34:1465-1474.
27. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201. 10.1136/ard.2003.019992, 1755350, 15458956.
28. Hammer HB, Odegard S, Syversen SW, Landewe R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK. Calprotectin (a major S100 leukocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:150-154. 10.1136/ard.2008.103739, 19095696.
29. Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1675-1678. 10.1136/ard.2007.071910, 2095335, 17666448.
30. van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB, Dijkmans BA, Lems WF. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1623-1628. 10.1136/ard.2009.121764, 20525836.
31. Knudsen LS, Klarlund M, Skjodt H, Jensen T, Ostergaard M, Jensen KE, Hansen MS, Hetland ML, Nielsen HJ, Johansen JS. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis: relationship to disease activity and radiographic outcome. J Rheumatol 2008, 35:1277-1287.
32. van Tuyl LH, Lems WF, Voskuyl AE, Kerstens PJ, Garnero P, Dijkmans BA, Boers M. Tight control and intensified COBRA combination therapy in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008, 67:1574-1577.